Meeting
2021 ASCO Annual Meeting
Results from CONTESSA 2: A multinational, multicenter, phase 2 study of tesetaxel (T) plus a reduced dose of capecitabine (C) in patients (pts) with hormone receptor + (HR+), HER2- metastatic breast cancer (MBC) not previously treated with a taxane.
Authors
Lee S. Schwartzberg
West Cancer Center, Memphis, TN
Lee S. Schwartzberg , Igor Bondarenko , Sara M. Tolaney , Andrew David Seidman , Joyce O'Shaughnessy , Yaroslav V. Shparyk , Chi-Feng Chung , Yen-Shen Lu , Nuria Chic , Lawrence C. Panasci , Yee Soo Chae , Sabela Recalde , Yevhen Hotko , Patricia Gomez , Gail Lynn Shaw Wright , Noshir Anthony Dacosta , Sina Vatandoust , Joseph P. O'Connell , Thomas Wei , Hope S. Rugo
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer—Metastatic
Track
Breast Cancer
Sub Track
Hormone Receptor-Positive
Clinical Trial Registration Number
NCT03858972
Citation
J Clin Oncol 39, 2021 (suppl 15; abstr 1061)
DOI
10.1200/JCO.2021.39.15_suppl.1061
Abstract #
1061
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2019 ASCO Annual Meeting
CONTESSA: A multinational, multicenter, randomized, phase III registration study of tesetaxel plus a reduced dose of capecitabine in patients (pts) with HER2-, hormone receptor + (HR+) locally advanced or metastatic breast cancer (LA/MBC) who have previously received a taxane.
First Author: Joyce O'Shaughnessy
Poster
2018 ASCO Annual Meeting
Contessa: A multinational, multicenter, randomized, phase 3 registration study of tesetaxel in patients (Pts) with HER2-, hormone receptor + (HR+) locally advanced or metastatic breast cancer (MBC).
First Author: Joyce O'Shaughnessy
Poster
2018 ASCO Annual Meeting
Activity of tesetaxel, an oral taxane, given as a single-agent in patients (Pts) with HER2-, hormone receptor + (HR+) locally advanced or metastatic breast cancer (MBC) in a phase 2 study.
First Author: Andrew David Seidman
Poster
2012 ASCO Annual Meeting
Final analysis of phase II study of EZN-2208 (PEG-SN38) in metastatic breast cancer (MBC).
First Author: Cynthia R. C. Osborne